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Background: Stevens Johnson Syndrome and Erythema Multiforme are hypersensitivity skin
reactions generally arising in the context of multiple causes. Radiation therapy is con-
sidered to be one of these causes, although most reports are hindered by concomitant
medications.
Aim: The aim of this paper was to present a case of Stevens Johnson Syndrome arising in a
patient undergoing gynaecological brachytherapy with an unusual presentation.
Case: We describe a case of a 56-year-old woman with endometrial cancer undergoing adju-
vant gynaecological radiotherapy. While undergoing a gynaecological brachytherapy boost,
she developed bilateral conjunctivitis that progressed to oral mucositis and pruritic ery-
thema with sloughing of the skin on her arms and legs but not the torso or irradiated ﬁeldstevens Johnson (namely the vaginal mucosa).
Conclusion: This case illustrates the association of RT/SJS; however, it also raises the question
of patients undergoing RT being more susceptible to SJS as opposed to a direct cause of the
disease.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.. Background
rythema Multiforme (EM) is a mild immune-mediated skin
eaction characterised by targetoid lesions on the skin that
ay (EM major) or may not (EM minor) affect the mucosae.
tevens Johnson Syndrome (SJS) is a severe idiosyncratic
eaction characterised by fever and mucocutaneous lesions
eading to epidermal necrosis and sloughing. Both these noso-
ogic entities are often associated with medications, although
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oi:10.1016/j.rpor.2011.02.002they might be triggered by other causes such as infections,
vaccinations and foods.1
The association of radiation therapy (RT) and Erythema
Multiforme or Stevens Johnson Syndrome has been described
in the literature in several reports2–13; however, most of these
describe cases of radiation therapy in association with med-
ications, phenytoin being the most prevalent of these.10–13
There is, however, a report of sparing SJS in irradiated ﬁelds in
a patient undergoing radiotherapy.14
Weexperienced a case of SJS in apatient undergoing gynae-
cological brachytherapy and report it here.
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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2. Case report
A 56-year-old Caucasian woman with a history of hyper-
tension (medicated with irbesartan and hidroclorothiazide
association) and osteoporosis (medicated with weekly alen-
dronic acid) was diagnosed with an endometrial adenocar-
cinoma grade I stage IIB. She underwent hysterosalpingo-
oophorectomy with lymphadenectomy. Eight weeks later, she
received 50.4Gy in 28 fractions of 1.8Gy with a box technique
using 15MeVphotons over 6weekswith grade I genito-urinary
toxicity, but without skin toxicity. Subsequently, she started
a high dose-rate brachytherapy boost, with an intended full
dose of 24Gy in 4 weekly fractions of 6Gy with a 30mm wide
vaginal cylinder.
A few days after the second fraction, a bilateral ocu-
lar hyperaemia with pruritus appeared. The patient was
referred to an ophthalmologist, who prescribed ocular clo-
ramphenicol. However, there was no improvement and these
symptoms soon progressed to mild dysphagia. Except for
the ocular antibiotic, no medication had been introduced
during the post-surgery period. During pre-fraction obser-
vation an oral mucositis characterised by erosions and
crusting as well as oedema of the lips and tongue were
recognised. The vaginal mucosa was discretely hyperaemic
and irregular, but there were no other observable lesions
or vaginal discharge. She underwent the third fraction of
brachytherapy; however, a few days later there was symp-
tomatic progression with skin pain and erythroderma that
progressed to targetoid patches of necrosis with epidermal
detachment on her arms and legs, sparing the soles but
not the palms. Thorax and scalp were also spared. She was
referred to emergency and was admitted at the Dermatology
Department.
Radiation therapy was discontinued on admission. Periph-
eral blood tests revealed a mild anaemia (haemoglobin
– 11.8 g/dL) and a slight elevation in C reactive protein
(1.3mg/dL), but no leucocytosis or eosinophilia.
A biopsy of the lesions was performed and revealed a diag-
nosis consistent with Erythema Multiforme.
The patient was given wound and ocular care, as well as
treatmentwith hydroxizine (25mg/day) and oral prednisolone
(20mg once daily). During hospitalisation, the lesions became
more intense, including the aforementioned pruritus, even-
tually progressing to vesicles and bullae with skin sloughing
within days. However, they never spread out of the limb
area, sparing the torso, the soles and the scalp. The mucosal
lesions were also conﬁned to the oral and ocular mucosae.
The lesions gradually stabilized and regressed over two
weeks.
The patient was discharged after 20days. She undertook
her last brachytherapy fraction on the day of her discharge,
with no subsequent development of SJS or EM in a 3 month
follow-up.3. Discussion
This case illustrates the association between radiation
therapy and EM/SJS that has been reported in severaliotherapy 1 6 ( 2 0 1 1 ) 115–117
instances. However, as mentioned above, most reports
of this association are hindered by the introduction of
other medications.2–13 Of these, the most prevalent are
phenytoin10–13 and amifostine,5,6 but other medications
have also been implicated, such as chemotherapy agents
(gemcitabine,3 temozolamide4) and other anticonvulsants
(phenobarbital,7 diphenylhydantoin8). There is also one pub-
lished case of sparing SJS in irradiated ﬁelds of a patient
undergoing phenobarbital and palliative radiation therapy for
bone metastases.14
The peculiarity underlying this case rests with its presen-
tation and evolution. Our patient was not submitted to new
drug therapies while undergoing radiation. She maintained
her hypertension (irbesartan and hydrochlorothiazide associ-
ation) and osteoporosis (alendronate) usual medication, and
despite one case report on SJS caused by hydrochlorothiazide
in associationwith allopurinol15 and a study implicating alen-
dronate as a possible cause of EM,16 she had taken these
compounds for years without any reaction. However, she
had also undergone external beam radiation therapy before
brachytherapy without severe skin toxicity.
Furthermore, the skin reaction started in the ocular and
oral mucosae before spreading to the limbs. The whole torso
was spared including the irradiated areas, namely the pelvic
area and vaginal mucosa, where a hyperaemia and irregular-
ity can be attributed to grade I radiomucositis, although this
might constitute a confounding factor leading to a bias in this
case. This is, to our knowledge, the ﬁrst such instance, since
in most cases of SJS/RT association the onset of SJS is on the
irradiated ﬁelds. Even though the pathological report issued
a diagnosis of EM, this can be attributed to a biopsy of an
incipient lesion, as the lesions progressed to sloughing of the
skin.17
The lack of complications after the last fraction of
brachytherapy raises the question of a lack of causality
between radiation and the onset of this disease, since it can
also be attributed to environmental factors. The patient was
however still under corticosteroids and hidroxizine, which
may have spared this complication, since radiation is known
to produce oxidative reaction intermediates that are involved
in hypersensitivity reactions.18
However, considering that RT is often seen as a cause
of EM/SJS, the lack of data on these pathologies arising in
patients not undergoing concomitant novel pharmacological
therapies should raise the question of it being a factor leading
to an increase in susceptibility as opposed to a direct cause of
these syndromes.
4. Conclusion
We have described a case of Stevens Johnson Syndrome aris-
ing in a patient undergoing gynaecological brachytherapywith
an unusual presentation. This case demonstrates that this
syndrome may arise in patients undertaking radiation ther-
apy but not undergoing concomitant medications; however, it
also raises the question of a possible lack of causality between
RT/EM.
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